Understanding eGFR and Serum Creatinine: Formulas, Limitations, and Causes of Variability

Explains commonly used eGFR formulas (including CKD‑EPI 2021), how serum creatinine is affected by muscle mass and diet, the role of cystatin C, and key points for interpreting single values versus trends and common causes of transient changes.

Article type: Medical knowledge summary (intended readers: patients and families with kidney disease, dialysis, and transplant) Evidence type: Clinical guidelines / high-quality systematic reviews (6 references) Based on: PubMed public abstracts (full texts not read)

Explains commonly used eGFR formulas (including CKD‑EPI 2021), how serum creatinine is affected by muscle mass and diet, the role of cystatin C, and key points for interpreting single values versus trends and common causes of transient changes.

1) eGFR and Serum Creatinine: Basic Concepts

eGFR (estimated glomerular filtration rate) is a commonly used clinical indicator of kidney function, usually expressed in mL/min/1.73 m2; common estimating equations use serum creatinine or cystatin C or both as inputs. International guidelines recommend using equations that combine creatinine and cystatin C to improve accuracy, but cystatin C testing availability may be limited in some regions or by insurance coverage [3][6]. In Asian populations, revised equations such as CKD‑EPI 2021 have shown better performance in East Asian samples, but performance still varies by ethnic group and age, so clinicians should decide which equation to use based on the individual context [4][5][3].

2) CKD‑EPI 2021, EKFC and Other Equations: Differences and Local Performance

Multiple systematic reviews have noted that different eGFR equations perform differently across populations (for example East Asian or Chinese); CKD‑EPI‑2021 showed better consistency in East Asian data; EKFC, FAS and others have been proposed as alternative equations across age ranges or for specific populations [4][5][3]. KDIGO 2024 guidance emphasizes using eGFR together with urine albumin/creatinine ratio (ACR), and uses a persistent 3-month duration as the time standard to define chronic kidney disease (CKD) [3]. Clinically, choice of equation should consider local validation data, patient age and body size, and be determined by the physician based on the individual.

3) Why Serum Creatinine Sometimes Does Not Reflect the ‘True’ GFR: Effects of Muscle Mass, Diet and Hormones

Serum creatinine is closely related to muscle metabolism: increased muscle mass (for example after testosterone treatment or heavy resistance training) increases creatinine generation and may make creatinine-based eGFR appear reduced, which does not necessarily indicate kidney injury. A systematic analysis on gender-affirming hormone (testosterone) use reported that in the first 6–12 months after starting therapy a decline in eGFR (calculated by CKD‑EPI) is commonly seen; investigators attributed this mainly to increased creatinine generation (muscle mass changes) rather than kidney damage [2]. In addition, a high-protein diet can cause short-term hemodynamic changes and an increase in eGFR, but most clinical trials rely on creatinine-based estimates, and these changes may reflect physiological or transient adjustments without consistent biochemical evidence of kidney injury [1]. Therefore, interpreting kidney function solely from creatinine requires attention to individual muscle mass, diet, and recent treatments [1][2].

4) The Role of Cystatin C: Why Measure Both Markers?

Cystatin C is another biomarker commonly used to estimate GFR and has lower correlation with muscle mass; multiple guidelines and expert groups recommend using combined creatinine and cystatin C equations when muscle mass or body weight may interfere, to improve eGFR accuracy—especially in patients where precise dosing or treatment eligibility is required (e.g., cancer patients) [3][6]. However, cystatin C testing availability, cost, and standardization vary across healthcare systems, and clinical adoption should be discussed with physicians, hospital laboratories, and payers [3][6][4].

5) Single Test vs Long-Term Trend: When to Worry?

KDIGO bases CKD diagnosis and classification on persistence of abnormal kidney function or urine protein for at least 3 months; that is, a single high or low eGFR/creatinine does not necessarily indicate chronic kidney disease, but one must assess for reversible or temporary causes (such as recent dietary change, muscle mass change, acute illness or drug effects) [3][1][2]. Systematic reviews indicate that short-term interferences (e.g., changes in protein intake) can cause transient rises or falls in eGFR that do not necessarily represent renal parenchymal injury; thus clinicians commonly use trends (multiple measurements) together with urine testing (ACR) to determine the presence of persistent kidney dysfunction [1][3].

6) Common Situations That Cause Transient eGFR/Creatinine Changes (Clinical Considerations)

• Dietary factors: short-term high-protein intake can cause eGFR to rise (mainly due to hemodynamic changes or creatinine-estimate bias) but is not necessarily evidence of kidney damage [1].
• Changes in muscle mass or hormone therapy: increased muscle mass raises creatinine and may make creatinine-based eGFR fall, but this does not necessarily indicate kidney injury [2].
• Treatment- or drug-related factors: some therapies or drugs may alter renal blood flow or carry a risk of kidney injury; when determining drug dosing or treatment eligibility (e.g., antineoplastic agents), it is recommended to use equations that include cystatin C or, if necessary, confirm with measured GFR [6]. (Above points are summaries from systematic reviews and expert guidance; clinical cases should be judged by a physician based on the individual) [1][2][3][6].

7) Practical Clinical Questions to Discuss with Your Healthcare Team

When you receive eGFR or creatinine results, you can discuss the following with your doctor/pharmacist:

• Which eGFR equation was used for this test? (Is it CKD‑EPI 2021 / does it include cystatin C?) [4][3].
• Could my muscle mass, diet, or recent treatments affect the creatinine result? Do I need additional cystatin C testing or repeat measurements? [2][1][6].
• If drug dosing needs adjustment (especially renally cleared drugs, antineoplastic agents, anticoagulants, etc.), which eGFR estimate is recommended or is measured GFR required? [6][3].
• Does my eGFR/ACR meet criteria for chronic kidney disease (persistent ≥3 months)? How often should I be followed up? [3].
• If there is a large discrepancy (e.g., between creatinine-based eGFR and cystatin C estimate), what are the next confirmatory tests? (e.g., repeat blood/urine tests or direct GFR measurement) [6][3].

Limitations (Important)

This article is based only on provided PubMed/journal abstracts and the full texts or complete contents of the systematic syntheses were not read; statements in the text are based on the abstracts. For personalized diagnosis, medication adjustment or stopping medications, always discuss with your treating physician or pharmacist.

Medical disclaimer: This article is for general health education and information only. It does not constitute individual medical diagnosis, treatment advice, or a doctor–patient relationship. Medical research is continually updated, and study findings have their own scope and limitations. Every patient's condition, laboratory values, medications and treatment needs differ. Do not stop or adjust medication doses, change your diet or fluid intake, or alter dialysis or transplant treatment based on this article alone. For any medical questions, please consult your nephrologist or another qualified healthcare professional.

When to Seek Immediate Medical Attention

• Acute oliguria or anuria (markedly decreased urine output) — seek immediate medical attention or contact nephrology/emergency services [3][6].
• Shortness of breath, severe generalized edema or chest tightness (may indicate fluid imbalance or uremia) — seek immediate medical attention [3][6].
• Sudden change in consciousness, severe palpitations or muscle weakness (may be related to hyperkalemia) — seek immediate medical attention [3][6].
• Fever with flank pain or hematuria (suspected acute kidney infection or renal colic) — seek prompt medical care [3].
• During important drug therapy or chemotherapy, sudden rapid deterioration in kidney function or signs of drug adverse effects should prompt immediate contact with the treatment team [6].

Questions to Ask Your Healthcare Team

• Which equation was used for my eGFR this time? Was cystatin C included? [3][4].
• Could my muscle mass or recent diet (protein intake) affect the current creatinine / eGFR? Should it be retested or should cystatin C be added? [1][2].
• For drug dosing adjustments, which eGFR should the team use or is measured GFR recommended? [6].
• Do my results meet the CKD definition (persistent ≥3 months)? What is the recommended follow-up interval? [3].
• If there is a large discrepancy between creatinine and cystatin C estimates, what is the usual next step? Should I be referred to nephrology? [6][3].

Evidence Notes and Limitations

This article is mainly based on clinical guidelines and systematic reviews / meta-analyses abstracts. KDIGO 2024 and the American Society of Onco-Nephrology statement provide guidance (e.g., preference for combined creatinine and cystatin C equations) [3][6]; several systematic reviews and meta-analyses discuss the effects of diet, muscle mass and equation performance across populations [1][2][4][5]. Limitations include that many study abstracts rely on creatinine-based estimates and that the full texts were not reviewed here, so details and clinical applicability should be determined by your treating physician. This article is based on PubMed public abstracts and the full texts were not read.

This article is based on PubMed public abstracts and the full texts were not read; study populations, staging and comorbidities vary across studies and conclusions may not apply to every patient. All numeric targets and medication decisions must be determined by your healthcare team based on your individual situation.

References

[1] Teixeira Silva PR, Santos P, de Miranda Silva Nogueira PA, et al. Effects of High-Protein Diets on Renal Function and Body Composition in Adults Without Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomised Trials. Diabetes, obesity & metabolism. 2026. 臨床指引／高品質系統性回顧。 DOI: 10.1111/dom.70996. PMID: 42289790. PMC 開放全文：PMC13449083

[2] Tienforti D, Spagnolo L, Piscitani L, et al. Effects of gender affirming hormone therapy with testosterone on renal function of assigned female at birth transgender people: a meta-analysis. Frontiers in endocrinology. 2025. 臨床指引／高品質系統性回顧。 DOI: 10.3389/fendo.2025.1537838. PMID: 40575258. PMC 開放全文：PMC12198172

[3] Delanaye P, Jouret F, Cavalier É [International guidelines for the assessment of chronic kidney disease]. Revue medicale de Liege. 2025. 臨床指引／高品質系統性回顧。 PMID: 40518892.

[4] Siddiqui A, Lakhani S, Khan FA, et al. Performance evaluation of estimated glomerular filtration rate (eGFR) equations in Asia: A systematic review. The Malaysian journal of pathology. 2025. 臨床指引／高品質系統性回顧。 PMID: 40302474.

[5] Zhao L, Li HL, Liu M, et al. GFRs in Chinese CKD: A systematic review. Clinica chimica acta; international journal of clinical chemistry. 2025. 臨床指引／高品質系統性回顧。 DOI: 10.1016/j.cca.2025.120124. PMID: 39778610.

[6] Kitchlu A, Silva VTCE, Anand S, et al. Assessment of GFR in Patients with Cancer: A Statement from the American Society of Onco-Nephrology. Clinical journal of the American Society of Nephrology : CJASN. 2024. 臨床指引／高品質系統性回顧。 DOI: 10.2215/CJN.0000000000000508. PMID: 38848131. PMC 開放全文：PMC11321742

Article created: 2026-10-16｜Last medical literature check: 2026-10-16｜Last substantive content update: 2026-10-16 (source metadata checked against PubMed)